Talk:Transitional cell carcinoma

Could update refs for treatment of metastatic TCC
Currently uses a 2000 ref - See also : from Checkpoint Inhibitors and Urothelial Carcinoma: The Translational Paradigm - Rod57 (talk) 16:19, 3 March 2016 (UTC)
 * 2. Galsky MD, Chowdhury S, Bellmunt J, et al. Treatment patterns and outcomes in” real world” patients (pts) with metastatic urothelial cancer (UC). J Clin Oncol. 2013;31(suppl): abstr 4525.
 * 3. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006;42:50-4.
 * 4. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602-8.

2016 review of agents in clinical trials for metastatic urothelial carcinoma
New Agents for the Treatment of Advanced Bladder Cancer - covers many, but the immune checkpoint inhibitors (see p2 & table 2) sound the most promising. Summarised in Systemic Therapy for Urothelial Carcinoma: Is a Renaissance Around the Corner? - Rod57 (talk) 10:09, 7 July 2016 (UTC)

Removed nickname OR

 * It can extend from the kidney collecting system to the bladder - "Creeping Tumor".

The above was removed as not only is it written in an uncyclopedic tone but no other references exist for TCCs being called "creeping cancer"; in the above reference, it is simply a nickname that the authors obviously have come up (perhaps from nowhere) and not the medical community. --Qwerty Binary (talk) 14:05, 21 September 2016 (UTC)